Haematological Changes in Patients with Lymphoid Malignancies on Chemotherapy in Benin City, Edo State, Nigeria by Onuoha, Emmanuel . C. et al.
Journal of Medicine, Physiology and Biophysics                                                                                                                              www.iiste.org 
ISSN 2422-8427     An International Peer-reviewed Journal  
Vol.61, 2019 
 
34 
Haematological Changes in Patients with Lymphoid Malignancies 
on Chemotherapy in Benin City, Edo State, Nigeria 
 
Emmanuel . C. Onuoha 1*      Mabel .E. Ike2      Tracy .A. Diepreye 3      Ezekiel. F.Hallie4  
Vivian. A.  Maduka1      Nake. Nelson-Ebimie1       Jangfa. N. Nden1 
1. Medical Laboratory Unit, Medical Services, Federal University, Otuoke, Bayelsa State 
2. Department of Zoology, Faculty of Natural Sciences, University of Jos, Nigeria 
3.Pharmacy Unit, Medical Service Department, Federal University, Otuoke, Bayelsa State, Nigeria 
4. School of Pharmacy, University of Liberia, Monrovia, Liberia 
 
Abstract 
Chemotherapy continues to serve as the best option therapy in treating human malignancies that have undergone 
metastasis and cannot be managed solely by surgical removal or radiation. The aim of this study is to evaluate the 
clinical important of haematological parameters in the management of lymphoid malignancy patients on 
chemotherapy to ascertain the impact of such chemotherapy on them.. This study was carried out in one secondary 
and one tertiary health institution in Edo State. It was divided into three groups: lymphoid malignancy on 
chemotherapy, novel lymphoid malignancy and apparently healthy individuals as controls. Using aseptic 
precaution, 5ml of blood is collected into K2EDTA container for full blood count analysis using KX-21NSysmex 
automated Haematology analyser 2004 model and data were analysed using student t test. The comparison between 
novel lymphoid malignant patient and controls indicate WBC, lymphocytes and platelet count increase 
significantly (P <0.05) while RBC, HGB, HCT decrease significantly (P <0.05) when compared with control. 
However, MCV, MCH, MCHC, monocytes and granulocytes were not significant (P>0.05). The comparison  
between lymphoid malignant patient on chemotherapy and controls shows RBC, HGB, HCT decrease significantly 
when compared with control (P <0.05) while WBC, lymphocytes, platelet, MCV, MCH, MCHC, monocytes and 
granulocytes were not significant (P>0.05).When lymphoid malignant patient on chemotherapy and novel 
lymphoid malignant patient are compared, it shows RBC, HGB, HCT increase significantly when compared with 
novel lymphoid malignant patients (P <0.05) while WBC and MCHC decrease significantly (P <0.05). However, 
lymphocytes, platelet, MCV, MCH, monocytes and granulocytes were not significant (P>0.05). we can deduce 
that full blood count is highly clinically important for an effective management of lymphoid malignant patients on 
chemotherapy. 
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1. Introduction 
The summation of different malignant conditions from bone marrow cells and the lymphatic system origin is called 
Lymphoid malignancies (1). Genetic alteration in the bone marrow cell and lymphoid tissue at the surface area are 
the causes of these clonal diseases (2). Lymphoid malignancies include the following: acute lymphoblastic 
leukaemia (ALL), Chronic Lymphocytic leukaemia (CLL), prolymphocytic leukaemia (PLL),  hairy cell 
leukaemia (HCL) and lymphomas such as: Hodgkin Lymphoma (HL), Non-Hodgkin Lymphoma (NHL),  
myeloma, indolent lymphoma, aggressive lymphoma according to World Health Organisation (3).  
Chemotherapy continue to serve as the best option therapy in treating human malignancies that have 
undergone metastasis and cannot be managed solely by surgical removal or radiation (4). There was slow 
advancement in haematological chemotherapy in the first lap of twentieth century but rapidly development at last 
lap of twentieth century by certain important findings which cause a great change in the field of haematological 
chemotherapy for many terminal diseases. These important findings were (a) many antimetabolite and cytotoxic 
drugs development. (b) Tremendous development in blood product and supportive therapy permitting more 
intensive use of cytotoxic drug alone or in combination (c) Set of rule being developed for preemptive antibiotic 
treatment in immuno suppressed patient before microbiology laboratory results were available (d) Monoclonal 
antibodies advancement for management of different malignant and non malignant conditions (e) Recombinant 
proteins and more comprehension of basic techniques of cell growth, division, differentiation, migration and 
cellular death (5). 
A full blood count (FBC) is a blood test that gives detail information  about the kinds and numbers of cells in 
the blood, especially red blood cells, white blood cells and platelets. It also helps in the diagnosis of other 
opportunistic diseases  (6).  
Therefore, the aim of this study is to evaluate the clinical important of haematological parameters in the 
management of lymphoid malignancy patients on chemotherapy to ascertain the impact of such chemotherapy on 
them. 
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2. Materials aand Methods 
2.1 Study Area/Sample Size 
The study population composed the lymphoid malignant patients from 18 years and above. The total population 
of sixty (60) subjects was divided into three groups as follows:  
Group1: Twenty (20) lymphoid malignant patients on chemotherapy.  
Group2: Twenty (20) novel lymphoid malignant patients. ,              
Group3: Twenty (20) controls (those without lymphoid malignancy). 
The study was carried out in Benin City, Edo state. Blood samples collected and analyses were made for full blood 
count. Ethical clearance was obtained from ministry of health, Edo state ethical committee and oral consent was 
obtained from the patients before their names were inputted into the data collection form. 
 
2.2 Sample Collection  
Blood samples were collected using sterile EDTA. This was achieved by tying a tourniquet above a prominent 
vein, and a sterile swab used to clean the area to reduce the risk of contamination. With a sterile syringe, blood is 
collected from the vein and immediately put into an EDTA bottle. The blood was mixed gently to avoid 
coagulation. All samples collected were properly labeled send to haematlogy laboratory of University of Benin 
teaching hospital for processing within 2 hours of collection. 
 
2.3 Processing of Samples 
Full blood count was done by Sysmex Automated Hematology Analyzer Kx-21 within two hours of sample 
collection in EDTA container. This instrument uses electronic low-voltage direct current resistance principle: Cells 
are sized and counted by detecting and measuring changes in electrical resistance when a particle passes through 
a small aperture. 
                                                                                                                                                                       
3. Statistical Analysis 
The various laboratory data obtained was analysed using the Statistical Package for Social Sciences (SPSS) version 
16.  Results were expressed as mean ± standard deviation (SD) and student's t- test was used for comparison. 
Differences will be considered significant at an error probability of P less than 0.05.  
 
4. Results 
Table 1: Demographic and Clinical Characteristic of Lymphoid Malignant Patients 
Characteristic                             Total of Patients Number                Percentage (%) 
No. of patients                                       40 
Ages(years) 
25-40                                                       6                                                  15.0 
41-55                                                     11                                                  27.5 
56-70                                                     21                                                  52.5 
71-85                                                       2                                                    5.0 
Gender 
Male                                                      19                                                  47.5 
Female                                                   21                                                  52.5 
Lymphoid Malignancy 
Multiple Myeloma                                13                                                  32.5  
Hodgkin Lymphoma                             12                                                  30 
Non-Hodgkin Lymphoma                       6                                                  15 
Chronic Lymphocytic Leukaemia           9                                                  22.5     
 
The general demographic and clinical characteristics of lymphoid malignant patients were detailed in above 
Tables. The median age of all patients was 56 years (range 25-85 years). There were 19 (47.5%) males and 21 
(52.5%) females in the (1:1) ratio. The lymphoid malignant patients observed were: Multiple myeloma 13(32.5%), 
Hodgkin Lymphoma 12(30%), non-hodgkin lymphoma 6(15%) and Chronic Lymphocytic Leukaemia 9(22.5%).  
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Table 2: Comparison of Haematological Parameters between Noval  Lymphoid Malignancy and Control. 
Parameters                                        Controls                      not Chemotherapy                      t-value          p-value 
Full blood count 
Total White blood cells (103/ul)     5.13±1.27                           42.12± 32.06                           5.2                .000 
Red blood cells(106/ul)                  4.89± 0.57                           3.12 ±1.156                             5.8                .000 
Haemoglobin (g/dl)                       13.55 ±2.16                          8.4 ± 2.28                                9.68              .000 
Haematocrit value(%)                   41.2± 5.45                            24.97 ± 7.43                            9.137             .000 
Platelets counts(103/ul)                 239.85±52.27                     468.65± 411.64                         2.41               .026 
Differentials 
Lymphocytes(%)                           41.14 ±10.1                          56.06±  23.29                          3.16               .005 
Monocytes(%)                               12.59 ± 3.79                         19.16 ± 27.994                        1.034             .314 
Granulocytes(%)                          46.27± 25.12                          44.76± 25.12                             .221             .827 
Red cells index 
Mean Cell Volume (fl)                84.48±11.68                            82.01±8.62                                 .632             .535 
Mean cell Haemoglobin(pg)       27.72 ± 4.31                             27.79± 3.93                                .047             .963 
Mean Cell Haemoglobin  
Concentration(g/dl)                    32.70± 1.68                               33.77± 1.96                              1.898            0.073 
 
This table showed the comparison of haematological parameters between novel lymphoid malignant patients 
and controls; WBC, lymphocytes and platelet count increase significantly (P <0.05) while RBC, HGB, HCT 
decrease significantly (P <0.05) when compared with control. However, MCV, MCH, MCHC, monocytes and 
granulocytes were not significant (P>0.05). 
Table 3: Comparison of Haematological Parameters between Lymphoid Malignancy on Chemotherapy and 
Control. 
Parameters                                         Controls                     Chemotherapy                  t-value               p-value 
Full blood count 
Total White blood cells (103/ul)       5.13± 1.27                        6.26 ±3.45                      1.221                 0.237      
Red blood cells(106/ul)                      4.89±0.57                         3.92±0.81                      4.326                 0.000 
Haemoglobin (g/dl)                           13.55 ± 2.16                    10.60± 2.09                     4.469                0.000 
Haematocrit value(%)                        41.20± 5.45                     32.94± 5.43                    5.447                0.000 
Platelets counts(103/ul)                     239.85±52.27                 267.850 ±125.36               0.871               0.395 
Differentials  
Lymphocytes(%)                               41.14± 10.09                   44.12± 16.45                   0.667                0.513 
Monocytes(%)                                   12.59±3.79                      11.36 ±  3.45                   1.205                0.243 
Granulocytes(%)                               46.27± 11.35                    44.53±15.08                   0.414                 0.684 
Red cells index 
Mean Cell Volume (fl)                      84.48±11.68                     85.08± 11.15                  0,177                0.861 
Mean cell Haemoglobin(pg)              27.72± 4.31                      27.23 ± 3.87                   0.376                0.711      
Mean Cell Haemoglobin  
Concentration(g/dl)                            32.7  ±1.68                        32.11± 3.29                   0.617                0.544 
 
 
This table indicate the comparison of haematological parameters between lymphoid malignant patients on 
chemotherapy and controls, RBC, HGB, HCT decrease significantly when compared with control (P <0.05) while 
WBC, lymphocytes, platelet, MCV, MCH, MCHC, monocytes and granulocytes were not significant (P>0.05). 
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Table 4: Comparison of Haematological Parameters between Novel Lymphoid Malignancy And   Lymphoid 
Malignancy on Chemotherapy. 
Parameters                                        Chemotherapy              Not Chemotherapy             t-value          p-value 
Full blood count 
Total White blood cells (103/ul)          6.26± 3.45                    42.13± 32.06                     4.916            0.000 
Red blood cells(106/ul)                        3.92 ±0.81                      3.12±1.16                        2.434            0.025 
Haemoglobin (g/dl)                            10.60±2.10                      8.44±2.28                        2.832            0.011 
Haematocrit value(%)                        32.94 ± 32.94                  24.97± 7.43                      3.896            0.001 
Platelets counts(103/ul)                    267.85 ±125.36               468.65± 411.64                  1.933            0.068 
Differentials 
Lymphocytes(%)                               44.12± 16.45                   56.06 ± 23.29                    1.824            0.084 
Monocytes(%)                                   11.36± 3.45                      19.16 ± 27.99                   1.228            0.234  
Granulocytes(%)                                44.53±15.08                     44.76 ±25.12                    0.035           0.973 
Red cells index 
Mean Cell Volume (fl)                       85.08±11.15                    82.01 ± 8.616                    1.055           0.305 
Mean cell Haemoglobin(pg)              27.23±3.87                      27.79± 3.93                        0.579          0.569 
Mean Cell Haemoglobin  
Concentration(g/dl)                            32.11 ±3.29                     33.77± 1.96                        2.234          0.038 
 
This table shows the comparison of haematological parameters between lymphoid malignant patients on 
chemotherapy and novel lymphoid malignant patients, RBC, HGB, HCT increase significantly when compared 
with novel lymphoid malignant patients (P <0.05) while WBC and MCHC decrease significantly (P <0.05). 
However, lymphocytes, platelet, MCV, MCH, monocytes and granulocytes were not significant (P>0.05). 
 
5. Discussion 
Full blood count as one of the major haematological parameters is very vital test for diagnosis, evaluation, and 
treatment of lymphoid malignancy. It provides a lot of information related to bone marrow health which 
represented by number, type and morphology of blood cells. 
In table 2 showed the comparison of haematological parameters between novel lymphoid malignant patients 
and controls, we found WBC, lymphocytes and platelet count increase significantly (P <0.05) while RBC, HGB, 
HCT decrease significantly (P <0.05) when compared with control. However, MCV, MCH, MCHC, monocytes 
and granulocytes were not significant (P>0.05). 
When lymphoid malignant patient on chemotherapy and novel lymphoid malignant patient are compared in 
Table 4, it shows RBC, HGB, HCT increased significantly when compared with novel lymphoid malignant patients 
(P <0.05) while WBC and MCHC decreased significantly (P <0.05). However, lymphocytes, platelet, MCV, MCH, 
monocytes and granulocytes were not significant (P>0.05). 
This is in an agreement with Sendes study in which there was decreasing in HGB, RBC, HCT and significant 
increase in white blood cells (WBC) of chronic myeloid leukemia in comparison with control group (7). Similar 
study carried out with breast cancer also  showed significantly low RBC and HGB (8). 
In Table 2 and Table 4, we observed the total white cells count (WBC) increased significantly (P<0.05) in 
novel lymphoid malignant patients compared with control and those in chemotherapy. This increase may be due 
to the effect of lymphoid malignancy on red bone marrow and lymphatic system in which presence of many 
abnormal cells lead to decrease of bone marrow production of normal cells and increasing the number of cancerous 
cell production. This will lead to malfunction of the affected cell of the body (9).  
In the same Table 2 and Table 4, we also observed that RBC, HGB, HCT were significantly low (P<0.05) 
both novel malignant patients and those on chemotherapy compared with the controls. This may be due to the 
accumulation of the cancerous cells in lymph node, bone marrow and spleen causing swelling of these organs and 
repeated hemorrhage causing shortage in red blood cells number and hemoglobin concentration leading to anemia 
in those patients (9). Furthermore, metastasis that occurred in the red bone marrow sinuses secrete substances 
which induce osteolysis that destroys precursors of red blood cells and  stem cells responsible for blood cells 
formation and differentiation processes leading to shortage in red blood cells formation (10,11). Anemia also 
occurred due to chemotherapy side effect in gastrointestinal tract  affecting bone marrow which may lead to partial 
or stop of blood components production (12). 
The comparison between lymphoid malignant patient on chemotherapy and controls in table 3 shows RBC, 
HGB, HCT decrease significantly when compared with control (P <0.05) while WBC, lymphocytes, platelet, 
MCV, MCH, MCHC, monocytes and granulocytes were not significant (P>0.05). 
This indicate that the chemotherapy had great effect on WBC but must be monitor to avoid low immunity 
which can expose the patients to infections (13, 12, 14). 
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6. Conclusion 
In conclusion, it was discovered that novel lymphoid malignant patients were associated with leucocytosis, 
thrombocytosis and anaemia. It was also discovered that chemotherapy normalized leucocytes, reduce platelet 
count and improved the haematocrit value.  In the light of these findings, haematological parameters are essential 
diagnosis for effective management of lymphoid malignant patients in hospital and cancer centers. It can also be 
a monitoring tool on potency of chemotherapy. Future prospective trials evaluating the predictive value of these 
blood parameters on the chemotherapy regimens may be useful for tailoring the treatment in each case.  
We can finally deduce that full blood count is highly clinically important for an effective management of 
lymphoid malignant patients on chemotherapy.    
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